Project Grant R01AI199982
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $737K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $802,749 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into interleukin-33 driven thymopoiesis in allograft recipients treated with lymphoablation. The project examines how the thymus recovers T cell compartments after...
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $211,831 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop cyclic antifungal peptides targeting drug-resistant invasive fungal infections. The recipient is developing novel cyclic antifungal peptides (CAFPs) to combat Aspergillus fumigatus and Candida albicans infections resistant to current first-line...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $248,814 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for hit-to-lead drug development targeting Acanthamoeba keratitis. Purdue will optimize a novel chemical class of benzoxazepinoindazole inhibitors to develop potent drug candidates for treating Acanthamoeba keratitis, a difficult-to-resolve eye infection caused by free-living amoeba exposure during improper...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services, awarded The Ohio State University $354,416 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into novel peroxisome functions in Histoplasma capsulatum pathogenesis. The research will define the peroxisome proteome and metabolome in pathogenic-phase fungal cells to uncover new peroxisomal roles beyond known functions...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $684,405 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosal immunotherapies targeting recurrent urinary tract infections and inflammatory bowel disease. The funded research advances immunomodulation via self-assembled peptides (ISAP), a platform using modular supramolecular polypeptide nanomaterials designed to elicit neutralizing antibody responses against...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (doing business as Cleveland Clinic Lou Ruvo Center) $608,840 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the metabolic drivers of donor-specific antibody generation in solid organ transplant recipients. The project...